<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854645</url>
  </required_header>
  <id_info>
    <org_study_id>PT003006-00</org_study_id>
    <nct_id>NCT01854645</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)</brief_title>
  <official_title>A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to assess the efficacy and safety of treatment with
      PT003 (GFF MDI), PT005 (FF MDI), PT001 (GP MDI), and open-label tiotropium bromide inhalation
      powder compared with each other and Placebo MDI over 24 weeks in subjects with moderate to
      very severe COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24</measure>
    <time_frame>Baseline and at Week 24</time_frame>
    <description>Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks</measure>
    <time_frame>Baseline and Weeks 2 to 24</time_frame>
    <description>Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) over 24 weeks. FEV1 was assessed at multiple time points post-baseline,and a modelbased average of all visits starting from Week 2 through week 24 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ) Score</measure>
    <time_frame>Baseline and at Week 24</time_frame>
    <description>Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Ventolin Hydrofluoroalkane (HFA) Use</measure>
    <time_frame>Baseline and at Week 24</time_frame>
    <description>Change from baseline in average daily rescue Ventolin HFA use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of Action as Assessed by FEV1</measure>
    <time_frame>Assessed for 5- and 15-minute post dose on Day 1</time_frame>
    <description>Defined as the first time-point using the 5- and 15-minute post dose measurements where the difference in FEV1 from Placebo was statistically significant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1 Within 2 Hours Post-dose</measure>
    <time_frame>Baseline and at Week 24</time_frame>
    <description>Peak change from baseline in forced expiratory volume in 1 second (FEV1) within 2 hours post-dose</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">2103</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>GFF MDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) (PT003)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP MDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium (GP) MDI (PT001)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FF MDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol Fumarate (FF) MDI (PT005)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label tiotropium bromide inhalation powder</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo MDI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFF MDI</intervention_name>
    <description>GFF MDI administered as two puffs Bis in Di.e. Twice Daily (BID)</description>
    <arm_group_label>GFF MDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GP MDI</intervention_name>
    <description>GP MDI administered as two puffs BID</description>
    <arm_group_label>GP MDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF MDI</intervention_name>
    <description>FF MDI administered as two puffs BID</description>
    <arm_group_label>FF MDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)</intervention_name>
    <description>Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)</description>
    <arm_group_label>Open-label tiotropium bromide inhalation powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo MDI</intervention_name>
    <description>Inhaled placebo administered as two puffs BID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female subjects at least 40 years of age and no older than 80 at Visit 1.

          -  Subjects with an established clinical history of COPD as defined by the American
             Thoracic Society (ATS)/European Respiratory Society (ERS)

          -  Current or former smokers with a history of at least 10 pack-years of cigarette
             smoking.

          -  Average f the -60 and the -30 min pre-dose FEV1 assessments must be &lt; 80% predicted
             normal value calculated using National Health and Nutrition Examination Survey
             (NHANES) III reference equations.

          -  Subjects willing and, in the opinion of the investigator, able to adjust current COPD
             therapy as required by the protocol

        Key Exclusion Criteria:

          -  Significant diseases other than COPD, i.e. disease or condition which, in the opinion
             of the investigator, may put the patient at risk because of participation in the study
             or may influence either the results of the study or the subject's ability to
             participate in the study

          -  Current diagnosis of asthma or alpha-1 antitrypsin deficiency

          -  Other active pulmonary disease such as active tuberculosis, lung cancer,
             bronchiectasis, sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary
             pulmonary hypertension, or uncontrolled sleep apnea

          -  Hospitalized due to poorly controlled COPD within 3 months prior to screening or
             during the Screening Period

          -  Poorly controlled COPD, defined as acute worsening of COPD that requires treatment
             with oral corticosteroids or antibiotics within 6 weeks prior to screening or during
             the Screening Period

          -  Lower respiratory tract infections that required antibiotics within 6 weeks prior to
             screening or during the Screening Period

          -  Unstable ischemic heart disease, left ventricular failure, or documented myocardial
             infarction within 12 months of enrollment.

          -  Recent history of acute coronary syndrome, percutaneous coronary intervention,
             coronary artery bypass graft within the past three months

          -  Congestive heart failure (CHF) New York Heart Association (NYHA) Class III/IV)

          -  Clinically significant abnormal 12-lead ECG

          -  Abnormal liver function tests defined as aspartate transaminase (AST), alanine
             transaminase (ALT), or total bilirubin ≥ 1.5 times upper limit of normal at Visit 1
             and on repeat testing

          -  Cancer not in complete remission for at least five years

          -  History of hypersensitivity to β2-agonists, glycopyrronium or other muscarinic
             anticholinergics, lactose/milk protein or any component of the MDI

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Andalusia</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Pasedena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Lehigh Acres</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>River Forest</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Elwood</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Sunset</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Hollywood</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Ocean</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Oregon</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Murrells Inlet</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tullahoma</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Huntsville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Lufkin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Midvale</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>West Allis</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>New Lambton</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Wooloongabba</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Daw Park</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Toorak Gardens</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Otahuhu</city>
        <state>Aukland</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Caversham</city>
        <state>Dunedin</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Greenlane</city>
        <state>East Aukland</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Newtown</city>
        <state>Wellington</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4154&amp;filename=PT003006-02%20Protocol%20Amendment-FINAL-11Sept14_29Jun16_Redacted.pdf</url>
    <description>PT003006-02 Protocol and Amendment-FINAL-Redacted</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2013</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <results_first_submitted>May 20, 2016</results_first_submitted>
  <results_first_submitted_qc>February 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 28, 2017</results_first_posted>
  <disposition_first_submitted>July 7, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 7, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 30, 2015</disposition_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Conducted at 160 sites throughout the US, Australia, and New Zealand from June 2013 - February 2015. Study participation was a maximum of 32 weeks.</recruitment_details>
      <pre_assignment_details>Study was a multicenter, randomized, double-blind, parallel group, chronic dosing, active- and placebo-controlled study; each patient was randomized to receive 1 of 5 possible treatments over the course of a 24-week treatment period</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GFF MDI (PT003)</title>
          <description>Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) 14.4/9.6 mcg</description>
        </group>
        <group group_id="P2">
          <title>GP MDI (PT001)</title>
          <description>Glycopyrronium (GP) MDI 14.4 mcg</description>
        </group>
        <group group_id="P3">
          <title>FF MDI (PT005)</title>
          <description>Formoterol Fumarate (FF) MDI 9.6 mcg</description>
        </group>
        <group group_id="P4">
          <title>Spiriva® Handihaler® (Open-label)</title>
          <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo MDI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="527"/>
                <participants group_id="P2" count="451"/>
                <participants group_id="P3" count="452"/>
                <participants group_id="P4" count="453"/>
                <participants group_id="P5" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="429"/>
                <participants group_id="P2" count="345"/>
                <participants group_id="P3" count="370"/>
                <participants group_id="P4" count="391"/>
                <participants group_id="P5" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="62"/>
                <participants group_id="P5" count="60"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol-Specified Criteria</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reasons / Missing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>7 subjects were excluded from analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>GFF MDI (PT003)</title>
          <description>Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) 14.4/9.6 mcg</description>
        </group>
        <group group_id="B2">
          <title>GP MDI (PT001)</title>
          <description>Glycopyrronium (GP) MDI 14.4 mcg</description>
        </group>
        <group group_id="B3">
          <title>FF MDI (PT005)</title>
          <description>Formoterol Fumarate (FF) MDI 9.6 mcg</description>
        </group>
        <group group_id="B4">
          <title>Spiriva® Handihaler® (Open-label)</title>
          <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo MDI</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="526"/>
            <count group_id="B2" value="451"/>
            <count group_id="B3" value="449"/>
            <count group_id="B4" value="451"/>
            <count group_id="B5" value="219"/>
            <count group_id="B6" value="2096"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.6" spread="8.4"/>
                    <measurement group_id="B2" value="62.9" spread="8.4"/>
                    <measurement group_id="B3" value="63.0" spread="8.3"/>
                    <measurement group_id="B4" value="63.0" spread="8.6"/>
                    <measurement group_id="B5" value="62.5" spread="8.3"/>
                    <measurement group_id="B6" value="62.8" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="203"/>
                    <measurement group_id="B4" value="182"/>
                    <measurement group_id="B5" value="97"/>
                    <measurement group_id="B6" value="914"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="290"/>
                    <measurement group_id="B2" value="255"/>
                    <measurement group_id="B3" value="246"/>
                    <measurement group_id="B4" value="269"/>
                    <measurement group_id="B5" value="122"/>
                    <measurement group_id="B6" value="1182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24</title>
        <description>Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at Week 24</description>
        <time_frame>Baseline and at Week 24</time_frame>
        <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) 14.4/9.6 mcg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>Glycopyrronium (GP) MDI 14.4 mcg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI (PT005)</title>
            <description>Formoterol Fumarate (FF) MDI 9.6 mcg</description>
          </group>
          <group group_id="O4">
            <title>Spiriva® Handihaler® (Open-label)</title>
            <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24</title>
          <description>Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at Week 24</description>
          <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="344"/>
                <count group_id="O3" value="367"/>
                <count group_id="O4" value="390"/>
                <count group_id="O5" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.126" lower_limit="0.107" upper_limit="0.145"/>
                    <measurement group_id="O2" value="0.066" lower_limit="0.045" upper_limit="0.087"/>
                    <measurement group_id="O3" value="0.062" lower_limit="0.041" upper_limit="0.082"/>
                    <measurement group_id="O4" value="0.105" lower_limit="0.084" upper_limit="0.125"/>
                    <measurement group_id="O5" value="-0.024" lower_limit="-0.055" upper_limit="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks</title>
        <description>Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) over 24 weeks. FEV1 was assessed at multiple time points post-baseline,and a modelbased average of all visits starting from Week 2 through week 24 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.</description>
        <time_frame>Baseline and Weeks 2 to 24</time_frame>
        <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) 14.4/9.6 mcg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>Glycopyrronium (GP) MDI 14.4 mcg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI (PT005)</title>
            <description>Formoterol Fumarate (FF) MDI 9.6 mcg</description>
          </group>
          <group group_id="O4">
            <title>Spiriva® Handihaler® (Open-label)</title>
            <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks</title>
          <description>Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) over 24 weeks. FEV1 was assessed at multiple time points post-baseline,and a modelbased average of all visits starting from Week 2 through week 24 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.</description>
          <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="440"/>
                <count group_id="O3" value="439"/>
                <count group_id="O4" value="446"/>
                <count group_id="O5" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.150" lower_limit="0.136" upper_limit="0.164"/>
                    <measurement group_id="O2" value="0.091" lower_limit="0.076" upper_limit="0.106"/>
                    <measurement group_id="O3" value="0.086" lower_limit="0.071" upper_limit="0.101"/>
                    <measurement group_id="O4" value="0.122" lower_limit="0.107" upper_limit="0.137"/>
                    <measurement group_id="O5" value="-0.007" lower_limit="-0.029" upper_limit="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St. George's Respiratory Questionnaire (SGRQ) Score</title>
        <description>Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.</description>
        <time_frame>Baseline and at Week 24</time_frame>
        <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) 14.4/9.6 mcg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>Glycopyrronium (GP) MDI 14.4 mcg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI (PT005)</title>
            <description>Formoterol Fumarate (FF) MDI 9.6 mcg</description>
          </group>
          <group group_id="O4">
            <title>Spiriva® Handihaler® (Open-label)</title>
            <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>St. George's Respiratory Questionnaire (SGRQ) Score</title>
          <description>Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.</description>
          <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="425"/>
                <count group_id="O3" value="434"/>
                <count group_id="O4" value="435"/>
                <count group_id="O5" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" lower_limit="-4.0" upper_limit="-2.2"/>
                    <measurement group_id="O2" value="-1.2" lower_limit="-2.2" upper_limit="-0.2"/>
                    <measurement group_id="O3" value="-2.4" lower_limit="-3.4" upper_limit="-1.4"/>
                    <measurement group_id="O4" value="-2.7" lower_limit="-3.6" upper_limit="-1.7"/>
                    <measurement group_id="O5" value="-0.8" lower_limit="-2.2" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Ventolin Hydrofluoroalkane (HFA) Use</title>
        <description>Change from baseline in average daily rescue Ventolin HFA use</description>
        <time_frame>Baseline and at Week 24</time_frame>
        <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) 14.4/9.6 mcg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>Glycopyrronium (GP) MDI 14.4 mcg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI (PT005)</title>
            <description>Formoterol Fumarate (FF) MDI 9.6 mcg</description>
          </group>
          <group group_id="O4">
            <title>Spiriva® Handihaler® (Open-label)</title>
            <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Ventolin Hydrofluoroalkane (HFA) Use</title>
          <description>Change from baseline in average daily rescue Ventolin HFA use</description>
          <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure</population>
          <units>Puffs / Day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="449"/>
                <count group_id="O3" value="446"/>
                <count group_id="O4" value="449"/>
                <count group_id="O5" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-1.0" upper_limit="-0.6"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-0.7" upper_limit="-0.3"/>
                    <measurement group_id="O3" value="-0.8" lower_limit="-1.0" upper_limit="-0.6"/>
                    <measurement group_id="O4" value="-0.4" lower_limit="-0.6" upper_limit="-0.2"/>
                    <measurement group_id="O5" value="0.3" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Onset of Action as Assessed by FEV1</title>
        <description>Defined as the first time-point using the 5- and 15-minute post dose measurements where the difference in FEV1 from Placebo was statistically significant</description>
        <time_frame>Assessed for 5- and 15-minute post dose on Day 1</time_frame>
        <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) 14.4/9.6 mcg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>Glycopyrronium (GP) MDI 14.4 mcg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI (PT005)</title>
            <description>Formoterol Fumarate (FF) MDI 9.6 mcg</description>
          </group>
          <group group_id="O4">
            <title>Spiriva® Handihaler® (Open-label)</title>
            <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Onset of Action as Assessed by FEV1</title>
          <description>Defined as the first time-point using the 5- and 15-minute post dose measurements where the difference in FEV1 from Placebo was statistically significant</description>
          <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="363"/>
                <count group_id="O3" value="366"/>
                <count group_id="O4" value="364"/>
                <count group_id="O5" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.185" lower_limit="0.175" upper_limit="0.195"/>
                    <measurement group_id="O2" value="0.042" lower_limit="0.031" upper_limit="0.053"/>
                    <measurement group_id="O3" value="0.182" lower_limit="0.171" upper_limit="0.193"/>
                    <measurement group_id="O4" value="0.048" lower_limit="0.037" upper_limit="0.059"/>
                    <measurement group_id="O5" value="-0.002" lower_limit="-0.017" upper_limit="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.226" lower_limit="0.216" upper_limit="0.237"/>
                    <measurement group_id="O2" value="0.101" lower_limit="0.090" upper_limit="0.113"/>
                    <measurement group_id="O3" value="0.212" lower_limit="0.201" upper_limit="0.224"/>
                    <measurement group_id="O4" value="0.117" lower_limit="0.105" upper_limit="0.129"/>
                    <measurement group_id="O5" value="0.022" lower_limit="0.005" upper_limit="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At 5 min post dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At 15 min post dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At 5 min post dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At 15 min post dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At 5 min post dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At 15 min post dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1 Within 2 Hours Post-dose</title>
        <description>Peak change from baseline in forced expiratory volume in 1 second (FEV1) within 2 hours post-dose</description>
        <time_frame>Baseline and at Week 24</time_frame>
        <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) 14.4/9.6 mcg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>Glycopyrronium (GP) MDI 14.4 mcg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI (PT005)</title>
            <description>Formoterol Fumarate (FF) MDI 9.6 mcg</description>
          </group>
          <group group_id="O4">
            <title>Spiriva® Handihaler® (Open-label)</title>
            <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 Within 2 Hours Post-dose</title>
          <description>Peak change from baseline in forced expiratory volume in 1 second (FEV1) within 2 hours post-dose</description>
          <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="367"/>
                <count group_id="O4" value="388"/>
                <count group_id="O5" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.356" lower_limit="0.335" upper_limit="0.377"/>
                    <measurement group_id="O2" value="0.223" lower_limit="0.200" upper_limit="0.246"/>
                    <measurement group_id="O3" value="0.263" lower_limit="0.240" upper_limit="0.285"/>
                    <measurement group_id="O4" value="0.259" lower_limit="0.237" upper_limit="0.281"/>
                    <measurement group_id="O5" value="0.065" lower_limit="0.031" upper_limit="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs and AEs were collected throughout study participation and for two weeks after study completion.</time_frame>
      <desc>Safety population included all participants who received at least one dose of investigational drug participants were included in safety population according to the investigational drug received</desc>
      <group_list>
        <group group_id="E1">
          <title>GFF MDI (PT003)</title>
          <description>Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) 14.4/9.6 mcg</description>
        </group>
        <group group_id="E2">
          <title>GP MDI (PT001)</title>
          <description>Glycopyrronium (GP) MDI 14.4 mcg</description>
        </group>
        <group group_id="E3">
          <title>FF MDI (PT005)</title>
          <description>Formoterol Fumarate (FF) MDI 9.6 mcg</description>
        </group>
        <group group_id="E4">
          <title>Spiriva® Handihaler® (Open-label)</title>
          <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo MDI</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="451"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Inflamation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="526"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Opthalmic herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Afferent loop syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer stage 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Translational cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="526"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="451"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="452"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="451"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Epistatxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="526"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="451"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="45" subjects_affected="43" subjects_at_risk="526"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="451"/>
                <counts group_id="E3" events="32" subjects_affected="28" subjects_at_risk="452"/>
                <counts group_id="E4" events="26" subjects_affected="26" subjects_at_risk="451"/>
                <counts group_id="E5" events="21" subjects_affected="18" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="526"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="451"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="452"/>
                <counts group_id="E4" events="18" subjects_affected="17" subjects_at_risk="451"/>
                <counts group_id="E5" events="16" subjects_affected="16" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="526"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="451"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="452"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="451"/>
                <counts group_id="E5" events="14" subjects_affected="13" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Reisner, MD, FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics, Inc</organization>
      <phone>973-975-0320</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

